Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 28.


Berg, David D, Wiviott, Stephen D, Scirica, Benjamin M, Zelniker, Thomas A, Goodrich, Erica L, Jarolim, Petr, Mosenzon, Ofri, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 8 more authors) (2021) A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. DIABETES CARE, 44 (11). pp. 2573-2581.


Cahn, Avivit, Wiviott, Stephen D, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Leiter, Lawrence A, Bhatt, Deepak L
et al (show 8 more authors) (2021) Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses fromDECLARE-TIMI58. DIABETES OBESITY & METABOLISM, 23 (1). pp. 29-38.


Cahn, Avivit, Raz, Itamar, Leiter, Lawrence A, Mosenzon, Ofri, Murphy, Sabina A, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Bhatt, Deepak L, McGuire, Darren K
et al (show 5 more authors) (2021) Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. DIABETES CARE, 44 (5). pp. 1159-1167.


De Caterina, Raffaele, Procopio, Antonio, Lopez Sendon, Jose-Luis, Raev, Dimitar, Mehta, Shamir R, Opolski, Grzegorz, Oldgren, Jonas, Steg, Philippe Gabriel, Hohnloser, Stefan H, Lip, Gregory YH ORCID: 0000-0002-7566-1626
et al (show 7 more authors) (2020) Comparison of Dabigatran Plus a P2Y<sub>12</sub> Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. AMERICAN JOURNAL OF MEDICINE, 133 (11). pp. 1302-1312.


ten Berg, Jurrien M, Steg, Philippe Gabriel, Bhatt, Deepak L, Hohnloser, Stefan H, de Veer, Anne, Nordaby, Matias, Miede, Corinna, Kimura, Takeshi, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Oldgren, Jonas
et al (show 1 more authors) (2020) Comparison of the Effect of Age (&lt; 75 Versus ≥75) on the Efficacy and Safety of Dual Therapy (Dabigatran plus Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin plus Aspirin plus Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). AMERICAN JOURNAL OF CARDIOLOGY, 125 (5). pp. 735-743.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo HM, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit
et al (show 5 more authors) (2019) Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials. Circulation, 139 (17). pp. 2022-2031.


Raz, Itamar, Mosenzon, Ofri, Bonaca, Marc P, Cahn, Avivit, Kato, Eri T, Silverman, Michael G, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 5 more authors) (2018) DECLARE-TIMI 58: Participants' baseline characteristics. DIABETES OBESITY & METABOLISM, 20 (5). pp. 1102-1110.


Oldgren, Jonas, Steg, Philippe Gabriel, Hohnloser, Stefan H, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Kimura, Takeshi, Nordaby, Matias, Brueckmann, Martina, Kleine, Eva, ten Berg, Jurrien M, Bhatt, Deepak L
et al (show 1 more authors) (2019) Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. EUROPEAN HEART JOURNAL, 40 (19). 1553-+.


Bonaca, Marc P, Wiviott, Stephen D, Zelniker, Thomas A, Mosenzon, Ofri, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Goodrich, Erica L, De Mendonca Furtado, Remo Holanda, Wilding, John PH ORCID: 0000-0003-2839-8404
et al (show 8 more authors) (2020) Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation, 142 (8). pp. 734-747.


Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria
et al (show 11 more authors) (2022) Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. DIABETES CARE, 45 (10). pp. 2350-2359.


Zeymer, Uwe, Leiva, Orly, Hohnloser, Stefan H, Steg, Philippe Gabriel, Oldgren, Jonas, Nickenig, Georg, Kiss, Robert Gabor, Ongen, Zeki, Estrada, Jose Navarro, Ophuis, Ton Oude
et al (show 6 more authors) (2021) Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EUROINTERVENTION, 17 (6). 474-+.


Zelniker, Thomas A, Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P, Heerspink, Hiddo HJL, Cahn, Avivit, Goodrich, Erica L, Im, Kyungah, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 6 more authors) (2021) Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiology, 6 (7). pp. 801-810.


Kato, Eri T, Silverman, Michael G, Mosenzon, Ofri, Zelniker, Thomas A, Cahn, Avivit, Furtado, Remo HM, Kuder, Julia, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 13 more authors) (2019) Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. CIRCULATION, 139 (22). pp. 2528-2536.


Berry, Natalia C, Mauri, Laura, Steg, Philippe Gabriel, Bhatt, Deepak L, Hohnloser, Stefan H, Nordaby, Matias, Miede, Corinna, Kimura, Takeshi, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Oldgren, Jonas
et al (show 2 more authors) (2020) Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention A Subgroup Analysis From the REDUAL PCI Trial. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 13 (4). e008349-.


Mosenzon, Ofri, Wiviott, Stephen D, Cahn, Avivit, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Heerspink, Hiddo JL, Zelniker, Thomas A, Dwyer, Jamie P
et al (show 11 more authors) (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. LANCET DIABETES & ENDOCRINOLOGY, 7 (8). pp. 606-617.


Schechter, Meir, Wiviott, Stephen, Raz, Itamar, Goodrich, Erica L, Rozenberg, Aliza, Yanuv, Ilan, Murphy, Sabina A, Zelniker, Thomas A, Fredriksson, Martin, Johansson, Peter A
et al (show 9 more authors) (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. LANCET DIABETES & ENDOCRINOLOGY, 11 (4). pp. 233-241.


Pollack, Rena, Raz, Itamar, Wiviott, Stephen D, Goodrich, Erica L, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Mosenzon, Ofri, Langkilde, Anna Maria, Gause-Nilsson, Ingrid AM
et al (show 6 more authors) (2023) Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58. DIABETES CARE, 46 (1). pp. 156-164.


Furtado, Remo HM, Raz, Itamar, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John PH ORCID: 0000-0003-2839-8404, Aylward, Philip, Dalby, Anthony J
et al (show 10 more authors) (2022) Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. CIRCULATION, 145 (21). pp. 1581-1591.


Cahn, Avivit, Mosenzon, Ofri, Wiviott, Stephen D, Rozenberg, Aliza, Yanuv, Ilan, Goodrich, Erica L, Murphy, Sabina A, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K
et al (show 7 more authors) (2020) Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. DIABETES CARE, 43 (2). pp. 468-475.


Peterson, Benjamin E, Bhatt, Deepak L, Steg, Ph Gabriel, Oldgren, Jonas, Maeng, Michael, Zeymer, Uwe, Halvorsen, Sigrun, Hohnloser, Stefan H, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Kimura, Takeshi
et al (show 5 more authors) (2021) Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC-CARDIOVASCULAR INTERVENTIONS, 14 (7). pp. 768-780.


Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, Kyungah, Goodrich, Erica L, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Furtado, Remo HM
et al (show 5 more authors) (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. LANCET, 393 (10166). pp. 31-39.


Sambola, Antonia, Rello, Pau, Soriano, Toni, Bhatt, Deepak L, Pasupuleti, Vinay, Cannon, Christopher P, Gibson, C Michael, Dewilde, Willem JM, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Peterson, Eric D
et al (show 8 more authors) (2020) Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thrombosis research, 195. pp. 128-135.


Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K
et al (show 9 more authors) (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). pp. 1357-1368.


McEwan, Phil, Morgan, Angharad R, Boyce, Rebecca, Bergenheim, Klas, Gause-Nilsson, Ingrid AM, Bhatt, Deepak L, Leiter, Lawrence A, Johansson, Peter A, Mosenzon, Ofri, Cahn, Avivit
et al (show 1 more authors) (2021) The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. DIABETES OBESITY & METABOLISM, 23 (4). pp. 1020-1029.


Wiviott, Stephen D, Raz, Itamar, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Silverman, Michael G, Bansilal, Sameer, Bhatt, Deepak L, Leiter, Lawrence A
et al (show 6 more authors) (2018) The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. AMERICAN HEART JOURNAL, 200. pp. 83-89.


Eccleston, David S, Kim, Joseph M, ten Berg, Jurien M, Steg, P Gabriel, Bhatt, Deepak L, Hohnloser, Stefan H, de Veer, Anne, Nordaby, Matias, Miede, Corinna, Kimura, Takeshi
et al (show 3 more authors) (2021) The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after PCI in patients with atrial fibrillation (a RE-DUAL PCI subgroup analysis and comparison to other dual antithrombotic therapy trials). CLINICAL CARDIOLOGY, 44 (7). pp. 1002-1010.


O'Donoghue, Michelle L, Kato, Eri T, Mosenzon, Ofri, Murphy, Sabina A, Cahn, Avivit, Herrera, Marisol, Tankova, Tsvetalina, Smahelova, Alena, Merlini, Piera, Gause-Nilsson, Ingrid
et al (show 8 more authors) (2021) The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. DIABETOLOGIA, 64 (6). pp. 1226-1234.


Zwart, Bastiaan, Bor, Willem Lambertus ORCID: 0000-0002-3253-5961, de Veer, Anne Johanna Wilhelmina Maria, Mahmoodi, Bakhtawar Khan, Kelder, Johannes Christiaan, Lip, Gregory YH ORCID: 0000-0002-7566-1626, Bhatt, Deepak L, Cannon, Christopher P and Ten Berg, Jurriën Maria
(2022) A novel risk score to identify the need for triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a post hoc analysis of the RE-DUAL PCI trial. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 18 (4). e292-e302.

This list was generated on Sat Jan 20 08:21:14 2024 GMT.